RNAi Technology Market Size, Share, Offering (Product and Services), Therapeutics (Oncology, Ocular Disorders, Respiratory Disorders, Hepatitis B and C, and Others), Delivery Method (Soaking, Nanoparticles, Viral Vectors, and Others), Application (Drug Discovery & Development, Functional Genomics, and Others), End-Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, CROs & CMOs, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Till 2035, the market valuation is expected to reach USD 11.5 Billion.
• RNAi technology market size was worth USD 2.96 Billion in 2024.
• Target market is increasing at a CAGR of 14.7%.

RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. The RNAi technology market growth is driven by the increasing prevalence of genetic disorders, increased demand for therapies, rising demand for therapies targeting cancer, growing focus on neurological disorders, rising use of RNA interference in viral and infectious disease treatments, advancements in delivery technologies, and increased research and development.

AI Contribution in Target Market:

The convergence of artificial intelligence (AI) with the field of RNA biology has ushered in a new era of scientific discovery, providing unprecedented insights into the intricacies of RNA regulation at the molecular level. By analyzing vast datasets, AI/ML offers unprecedented opportunities to decode RNA’s complexities, characterize the composition and structure of RNA, uncover their function, decipher the intricate regulatory networks that govern their activity and determine their relevance and alterations in disease.

Key Drivers of Target Market:

Increasing Number of Patients with Genetic Disorder Stimulate Market Growth

The demand for sophisticated and focused treatments is increased day by day due to the growing incidence of genetic illnesses, and RNA interference (RNAi) technology has become one of the most promising approaches in this regard. The market for RNAi technology will probably boosted by this, which will raise investment, research, and development and result in more extensive use in the treatment of genetic disorders.

• For instance, there are an estimated 10,000 different types of single-gene diseases (also called monogenic diseases), which are diseases caused by mutations in a single gene. The World Health Organization estimates that 10 out of every 1000 people are affected. This means that between 70 million and 80 million people in the world are living with one of these diseases.

Advancement in Delivery Methods may Schedule to Lift the Market Growth

Advancements in delivery methods, such as nanotechnology-based delivery systems and non-transgenic delivery technologies, are expected to overcome the delivery hurdles of RNAi therapeutics. Ongoing research is focused on understanding the mechanisms of siRNA delivery and developing catalytic RNA vehicles to make RNAi-based cancer gene therapy more effective.

• For instance, in June 2023, Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the latest developments on its of GalAhead, GalNAc-RNAi therapeutic platforms and related pipeline programs.

Restraints:

Market Growth is Disturbed by Off-Target Effects

RNA interference (RNAi) is widely used in high-throughput reverse genetics screens for basic research and drug discovery. However, this technique is known to produce “off-target” effects, or phenotypic results caused by an RNAi reagent’s knockdown of unintended genes rather than the gene of interest. Off-target effects refer to unintended gene silencing. It occurs when the RNAi molecule binds to unintended targets. This can result in false positives or negatives in experimental results, making it difficult to interpret the data accurately.

• Counterbalance Statements: Off-target effects are regulated through multiple mechanisms within the cell, and their presence can greatly complicate the interpretation of experimental data.

Market is Hindered by Complex Patent Landscape

The complex patent landscape surrounding RNAi technology, encompassing various aspects from molecules to applications, has created uncertainty, hindered research and development, and limited accessibility due to high licensing costs and the risk of patent infringement lawsuits.

• Counterbalance Statements: The complex patent landscape for RNAi technology can be addressed by improving delivery methods, developing new technologies, and creating licensing agreements.

Opportunities:

Integration with Other Technologies will Unlock Key Opportunities for Market in Upcoming Years

The future of RNAi technology is also expected to involve integration with other technologies, such as CRISPR-Cas9, to create more precise and efficient gene editing tools. The combination of RNAi and CRISPR-Cas9 technologies has the potential to revolutionize the field of gene therapy and enable the development of personalized medicine.

• For instance, in June 2023, Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic RNAi gene therapies, announced a collaboration for adenoviral vector production. Curigin develops anticancer gene therapy products that utilize innovative genetically engineered viruses and novel RNAi technology to quickly and accurately block key disease-specific genetic signal pathways, effectively switching off genes responsible for tumor growth.

Offering, therapeutics, delivery mode, application, end-use, and region are segmentation components of market.

Offering

The market by offering is bifurcated into product and services. The product segment of has larger RNAi technology market share than services due to the high usage of kits and reagents, and the strong focus of pharmaceutical and biotechnology companies on research and development.

• For instance, in July 2024, Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced a partnership with Gore Range Capital LLC for establishment of a joint venture, Sagesse Bio, Inc., to advance its novel RNAi therapeutic products into aesthetic medicine.

Therapeutics

Assenting to therapeutics, the market is divided into oncology, ocular disorders, respiratory disorders, hepatitis B and C, and others. Among these oncology prevail the market by virtue of growing demand for cancer treatments.  

• For instance, in August 2023, Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the completion of all dosing regimens for its Phase I study of STP707 for the treatment of multiple solid tumors in patients with various types of late-stage cancers who did not respond to multiple rounds of other oncology treatments.

Delivery Mode

The market through delivery mode is categorized into soaking, nanoparticles, viral vectors, and others. The advantages of nanoparticles in terms of stability, cellular uptake, controlled release, and targeting specificity have positioned them as the leading delivery method in the RNAi technology market.

Application

The market by application, is divided into drug discovery & development, functional genomics, and others. The drug discovery & development is superior as compared to other applications due to its ability to precisely target genes.

End-Use

On the account of end use, the market distributed into pharmaceutical & biotechnology companies, academic & research institutes, CROs & CMOs, and others. However, pharmaceutical & biotechnology companies influence market expansion due to their ability to invest in and commercialize RNAi-based therapeutics, their established infrastructure, and their potential to bring these therapies to market.

Regional

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America is the largest region for RNAi technology, due to its strong research and development (R&D) infrastructure, favorable regulatory environment, and significant public and private investments.

• For instance, in January 2025, Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, announced the completion of a USD 97 million Series B financing to support Phase 1 clinical trials of the company’s investigational RNAi therapies for KCNT1-related epilepsy and Huntington’s disease.

Asia Pacific: This region is expected to be the fastest growing market for RNAi technology, driven by investments in research and development, government initiatives, and a growing focus on personalized medicine.

• For instance, January 2024, Shanghai Argo Biopharmaceutical Co., Ltd., a biotechnology company focused on the discovery and development of next-generation RNAi therapeutics, announced that it has entered into two exclusive license and collaboration agreements with Novartis PHARMA AG. Under the agreement, Argo granted Novartis an exclusive ex-Greater China license to develop and commercialize a Phase 1/2a clinical-stage program for cardiovascular disease treatment.

RNAi Technology Market Report Scope:

Segmentation:

By Offering:

• Product
  • miRNA
  • siRNA
  • Others
• Services
  • Custom siRNA Modification Services
  • RNAi Therapy Development Service
  • Others

By Therapeutics:

• Oncology
• Ocular Disorders
• Respiratory Disorders
• Hepatitis B and C
• Others

By Delivery Method:

• Soaking
• Nanoparticles
• Viral Vectors
• Others

By Application:

• Drug Discovery & Development
• Functional Genomics
• Others

By End Use:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• CROs & CMOs
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Companies actives in Rnai technology market includes Alnylam Pharmaceuticals, Inc., ARROWHEAD PHARMACEUTICALS, INC., Silence Therapeutics, Thermo Fisher Scientific Inc., Revvity Discovery Limited, Company, and among others. These key players are applying some of the key strategies for experiencing steady growth of the market such as developing new drug delivery technologies, improving rnai delivery techniques, increasing investments and collaborations, and so on.

List of Key Players in the Market:

• Alnylam Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Silence Therapeutics
• Thermo Fisher Scientific Inc.
• Revvity Discovery Limited, Company
• OriGene Technologies, Inc.
• QIAGEN
• Benitec Biopharma
• Sirnaomics
• SiRNAgen Therapeutics Corporation
• Switch Therapeutics
• Altogen Biosystems
• Creative Biolabs
• City Therapeutics
• Mirimus

• In January 2025, City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announced that it has entered into a strategic collaboration with global eye health leader Bausch + Lomb. Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
• In April 2020, Blackstone and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced the companies have entered into a broad strategic collaboration under which Blackstone will provide up to USD 2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.

Analyst View:      

Growing prevalence of genetic disorders, increased demand for cancer-targeting therapies, increased attention to neurological disorders, increased use of RNA interference in the treatment of viral and infectious diseases, improvements in delivery technologies, and increased research and development are all driving the growth of the RNAi technology market.

More Related Reports

Legal Technology Market
Financial Technology Market
Haptic Technology Market
Digital Scent Technology Market
Immersion Cooling Technology Market